ReviewPostgraduate medical journal2000
Hepatocellular carcinoma.
Review in Postgraduate medical journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Surgical resection versus liver transplant for patients with hepatocellular carcinoma.The Cochrane database of systematic reviews · 2013Pooled it
- The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions.Clinical and experimental immunology · 2023Review
- RIPK2: a promising target for cancer treatment.Frontiers in pharmacology · 2023Review
- Article
- Article
- Article
- Review
- PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.Cell death & disease · 2020Article
- Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.Clinical and molecular hepatology · 2020Article
- Overexpression of Hepatocyte Chemerin-156 Lowers Tumor Burden in a Murine Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma.International journal of molecular sciences · 2019Article
- Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma.Cancer management and research · 2018Article
- PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.Oncotarget · 2016Article
- Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Diseases (Basel, Switzerland) · 2015Review
- Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo.Scientific reports · 2015Article
- Article
- Identification of drivers from cancer genome diversity in hepatocellular carcinoma.International journal of molecular sciences · 2014Review
- RB tumor suppressive function in response to xenobiotic hepatocarcinogens.The American journal of pathology · 2014Article
- Prophylactic Role of Averrhoa carambola (Star Fruit) Extract against Chemically Induced Hepatocellular Carcinoma in Swiss Albino Mice.Advances in pharmacological sciences · 2014Article
- Holotransferrin enhances selective anticancer activity of artemisinin against human hepatocellular carcinoma cells.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013Article
- Comparative histomorphological review of rat and human hepatocellular proliferative lesions.Journal of toxicologic pathology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatocellular carcinoma is one of the 10 most common tumours, and the most common primary liver malignancy, in the world. In the majority of cases, it occurs against a background of hepatitis B or C viral infection and/or liver cirrhosis, and is associated with a dismal prognosis of a few months. Current treatments in routine clinical practice are surgical resection and liver transplantation, but these therapies are applicable to only a small proportion of patients and prolongation of survival is restricted. Other treatment options include intra-arterial chemotherapy, transcatheter arterial chemoembolisation, percutaneous ethanol injection, cryotherapy, thermotherapy, proton therapy, or a wide range of their possible combinations. The current lack of definitive data, however, limits the use of these therapies. Another option is gene therapy, which although in its infancy at the present time, may have a significant role to play in the future management of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.